Provista Diagnostics Appoints Susan Gross, M.D., As Chief Medical Officer

NEW YORK, March 1, 2016 /PRNewswire/ -- Provista Diagnostics Inc., a company developing and commercializing proteomic-based diagnostic, prognostic and monitoring tests for cancers affecting women, has appointed Susan Gross, M.D., as Chief Medical Officer. In this role, Dr. Gross will oversee and guide the continued clinical progress of the company's pipeline diagnostics and identify new diagnostic approaches for development.

Logo - http://photos.prnewswire.com/prnh/20160301/339037LOGO

Dr. Gross is a renowned expert in women's health and diagnostics and is recognized for her work in the development of commercially available screening tests used in prenatal care settings. She is a professor of Clinical Obstetrics & Gynecology and Women's Health, Pediatrics and Genetics at the Albert Einstein College of Medicine in New York City, and she has contributed to national guideline and policy development.

"Dr. Gross' expertise and track record will be an invaluable asset in Provista's work to deliver diagnostic technologies that close important clinical gaps and serve women's health needs," said David E. Reese, Ph.D., President and Chief Executive Officer, Provista Diagnostics Inc. "Dr. Gross will provide critical leadership in the year ahead as we advance our clinical development programs and look toward sharing the results of multiple clinical research studies on our lead diagnostic test, Videssa® Breast."

Dr. Gross joins Provista from Natera where she served as the Chief Medical Officer, overseeing the development of the company's prenatal screening tests. Dr. Gross is also the founding director of Einstein's Program for Jewish Genetic Health and founder of the Human Genetics Laboratory at Jacobi Medical Center, which was developed to provide underserved women with equal access to state-of-the-art prenatal genetic services.

"The opportunity to advance Provista's novel pipeline of diagnostics aligns perfectly with my passion for advancing the health and well-being of women," Dr. Gross said. "As Chief Medical Officer of Provista, my work will contribute to an important objective developing the diagnostics needed to catch cancers earlier and provide both clinicians and patients accurate information to make informed treatment decisions, with greater confidence and clarity."

Dr. Gross has authored more than 80 peer-reviewed publications and multiple book chapters. She received her medical degree from the University of Toronto, where she also completed a residency in obstetrics and gynecology and a fellowship in maternal-fetal medicine. She completed a second residency in medical genetics at the University of Tennessee, Memphis.

Dr. Gross is a fellow of the American Congress of Obstetricians and Gynecologists (ACOG), the American College of Medical Genetics and Genomics (ACMG) and the Royal College of Surgeons of Canada (RCSC).

About Provista

Provista Diagnostics is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic and monitoring tests designed to address the unmet needs in women's cancer, such as breast and gynecologic cancers. Provista Diagnostics' state-of-the-art, high-complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and certified by the Centers for Medicare and Medicaid Services (CMS) to be compliant with the Clinical Laboratory Improvement Amendments (CLIA).

Additional information about Provista Diagnostics is available at http://ProvistaDx.com/

Information about Provista Diagnostics' clinical trials is available at http://ClinicalTrials.gov/

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista's actual results may differ materially due to a number of factors, many of which are beyond Provista's ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

Media Contact:
Susan LaMacchia
212-202-3174

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/provista-diagnostics-appoints-susan-gross-md-as-chief-medical-officer-300228569.html

SOURCE Provista Diagnostics

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.